Regentis Biomaterials Ltd（RGNT）股票分析

$1.180

+0.010 (+0.85%)收盘时

Loading chart…

最高: 1.220
开盘: 1.172
成交量加权均价: 1.19
成交量: 23.20K
市值: —
最低: 1.160
成交额: 27.53K
企业价值/息税折旧摊销前利润（TTM）: 0.00

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

www.regentis.co.il

AI 分析 of Regentis Biomaterials Ltd (RGNT)

卖出

Regentis Biomaterials Ltd is not a good buy right now due to its extremely low RSI of 26.439, indicating oversold conditions, and a staggering year-to-date decline of 82.49%.

估值指标

Regentis Biomaterials Ltd（RGNT）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。

预期市盈率

严重低估

5 年均值 P/E

0.00

当前P/E

0.00

高估

0.00

低估

0.00

预期 EV/EBITDA

严重低估

5 年均值 EV/EBITDA

0.00

当前EV/EBITDA

0.00

高估

0.00

低估

0.00

预期市销率

严重低估

5 年均值 P/S

0.00

当前P/S

0.00

高估

0.00

低估

0.00

事件时间线

2026-10-12 (ET)